(Boursier.com) — Eurobio Scientific has signed an exclusive worldwide license agreement with Dr. Nino Guy Cassuto for the development, manufacture and marketing of a new test based on his patents relating to a new method for selecting spermatozoa, in particular for medically assisted procreation ( LDCs).
Development of a new proprietary test
In this context, Eurobio Scientific proposes the development, validation and marketing of a test for the quantification by qRT-PCR of genetic markers identified by Dr. Cassuto for the screening of patients at risk of infertility. This test, which will complement the spermogram carried out routinely, will give a more precise approach in the exploration of male fertility.
This new molecular biology test, designed and developed by Eurobio Scientific R&D, will be produced in-house at its premises in Ulis, and should be available during the second half of 2022 in its RUO version for hospital and private laboratories, both in France and internationally.
Growing market
In general, the global market for assisted reproductive technologies (ART) is growing every year worldwide. Growth is expected to average around 10% per year to reach $45 billion in 2025, with just over 11% growth for IVF. Currently, approximately 62,000 IVF and 50,000 inseminations are performed each year in France.
In addition to these ART acts, there are a number of preparatory medical acts which result in the performance of around 370,000 spermograms per year, which would translate on a European scale into an overall potential of around 2 million analyzes per year which could be supplemented by the added value provided by a new PCR test,
The development of this new test by Eurobio Scientific is therefore part of a certain standardization of practices related to assisted reproduction, standardization made necessary by the continuous growth in the number of procedures.
©2022 Boursier.com